Ludwig Enterprises, Inc. operates as a genomic technology focused on developing testing approaches for inflammation-related chronic diseases, including cancers in the United States. The company integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits for cancer identification. It offers mRNA-based screening to provide early insights of potential health risks. The company develops Revealia Breast test, a non-invasive cheek swab screening kit designed to identify and analyze molecular signatures in mRNA expression associated with inflammation-related biological processes associated with the presence of breast cancer. Ludwig Enterprises, Inc. was founded in 1988 and is based in Miami, Florida.